Results 141 to 150 of about 95,391 (321)

Everolimus-eluting stents or bypass surgery for multivessel coronary disease [PDF]

, 2015
Copyright © 2015 Massachusetts Medical Society. BACKGROUND: Results of trials and registry studies have shown lower long-term mortality after coronary-artery bypass grafting (CABG) than after percutaneous coronary intervention (PCI) among patients with ...
Bangalore, Sripal, Blecker, Saul, Guo, Yu, Hannan, Edward L., Samadashvili, Zaza, Xu, Jinfeng   +5 more
core   +1 more source

Drug‐Coated Balloon‐Based Versus Drug‐Eluting Stent‐Only Treatment for Large Vessel Coronary Artery Disease

Catheterization and Cardiovascular Interventions, Volume 106, Issue 4, Page 2519-2527, October 1, 2025.
ABSTRACT Background Drug‐coated balloon (DCB) treatment has shown outcomes comparable to drug‐eluting stent (DES) in small vessel coronary disease. However, evidence for its application in large vessel coronary artery disease (CAD) remains limited. Aims This study evaluated the clinical impact of DCB‐based percutaneous coronary intervention (PCI) in ...
Eun‐Seok Shin, Mi Hee Jang, Sunwon Kim, Dong Oh Kang, Ae‐Young Her, Chang‐Bae Sohn   +5 more
wiley   +1 more source

First drug-eluting coronary stent approved [PDF]

, 2003
Cheryl Thompson
openalex   +1 more source

Stent Thrombosis With Drug-Eluting Stents

Journal of the American College of Cardiology, 2013
First-generation drug-eluting stents (DES), which impart the controlled release of sirolimus or paclitaxel from durable polymers to the vessel wall, have been consistently shown to reduce the risk of restenosis and target vessel revascularization compared with bare metal stents (BMS).
T. Palmerini, BIONDI ZOCCAI, GIUSEPPE, D. Della Riva, A. Mariani, P. Genereux, A. Branzi, G. W. Stone   +6 more
openaire   +3 more sources

Mathematical Modelling of Variable Porosity Coatings for Dual Drug Delivery [PDF]

, 2017
In this paper we describe a theoretical mathematical model of dual drug delivery from a durable polymer coated medical device. We demonstrate how the release rate of each drug may in principle be controlled by altering the initial loading configuration
McGinty, Sean, Pontrelli, Giuseppe
core  

Site‐Specific Antithrombotic Therapy: 24‐Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple‐Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus

Catheterization and Cardiovascular Interventions, Volume 106, Issue 4, Page 2770-2780, October 1, 2025.
ABSTRACT Background DESyne BDS Plus represents a novel triple drug therapy (TRx) applied on a coronary stent platform eluting the antiproliferative drug Sirolimus along with two anticoagulants (Rivaroxaban and Argatroban) to reduce the site‐specific thrombotic risk.
Stefan Verheye, Bert Ferdinande, Johan Bennett, Rodolfo Staico, Seif El‐Jack, Pim A. L. Tonino, Alexandre Abizaid, Ian Buysschaert, Douglas Scott, Madhav Menon, Gerard Wilkins, Dougal McClean, Tomas Kovarnik, Uwe Christians, Antoinette Neylon, Zlatko Mehmedbegovic, Pieter C. Smits, Marie‐Claude Morice, Mark Webster, the DESyne BDS Plus RCT Investigators   +19 more
wiley   +1 more source

Stent Fracture after Everolimus-Eluting Stent Implantation

Cardiology Research and Practice, 2011
Compared with bare-metal stents, drug-eluting stents (DES) have greatly reduced the risk of in-stent restenosis (ISR) by inhibiting neointimal growth. Nevertheless, DES are still prone to device failure, which may lead to cardiac events.
Ali S. Almasood, Xavier Freixa, Sohail Q. Khan, Peter H. Seidelin, Vladimír Džavík   +4 more
doaj   +1 more source

Long‐Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer‐Generation Drug‐Eluting Stents

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundPercutaneous coronary intervention (PCI) in patients with previous coronary artery bypass grafting (CABG) is associated with adverse clinical events.
Liefke C. van der Heijden, Marlies M. Kok, Paolo Zocca, Hanim Sen, Marije M. Löwik, Silvia Mariani, Frits H. A. F. de Man, Marc Hartmann, Martin G. Stoel, K. Gert van Houwelingen, J. (Hans) W. Louwerenburg, Gerard C. M. Linssen, Carine J. M. Doggen, Jan G. Grandjean, Clemens von Birgelen   +14 more
doaj   +1 more source

Drug eluting stents: are human and animal studies comparable? [PDF]

, 2003
Renu Virmani
openalex   +1 more source

Safety of Drug-Eluting Stents

Reviews in Cardiovascular Medicine, 2010
Significant evolution in catheter-based technologies for percutaneous coronary intervention has occurred since the introduction of coronary balloon angioplasty by Andreas Grüntzig in 1977. As balloon angioplasty was supplanted by bare metal stents and subsequently drug-eluting stents (DES), randomized comparative clinical trials have demonstrated a ...
openaire   +3 more sources